Class-B CpG-ODN formulated with a nanostructure induces type I interferons-dependent and CD4+T cell-independent CD8+T-Cell response against unconjugated protein antigen by Chiodetti, Ana Laura et al.
ORIGINAL RESEARCH
published: 10 October 2018
doi: 10.3389/fimmu.2018.02319






Medizinische Universität Wien, Austria
Sachin Kumar Deshmukh,






This article was submitted to
Vaccines and Molecular Therapeutics,
a section of the journal
Frontiers in Immunology
Received: 05 July 2018
Accepted: 18 September 2018
Published: 10 October 2018
Citation:
Chiodetti AL, Sánchez Vallecillo MF,
Dolina JS, Crespo MI, Marin C,
Schoenberger SP, Allemandi DA,
Palma SD, Pistoresi-Palencia MC,
Morón G and Maletto BA (2018)
Class-B CpG-ODN Formulated With a
Nanostructure Induces Type I






Class-B CpG-ODN Formulated With a
Nanostructure Induces Type I




Ana L. Chiodetti 1,2, María F. Sánchez Vallecillo 1,2, Joseph S. Dolina 3, María I. Crespo 1,2,
Constanza Marin 1,2, Stephen P. Schoenberger 3, Daniel A. Allemandi 4,5,
Santiago D. Palma 4,5, María C. Pistoresi-Palencia 1,2, Gabriel Morón 1,2 and
Belkys A. Maletto 1,2*
1Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba,
Argentina, 2Consejo Nacional de Investigaciones Científicas y Técnicas, Centro de Investigaciones en Bioquímica Clínica e
Inmunología, Córdoba, Argentina, 3Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La
Jolla, CA, United States, 4Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba,
Córdoba, Argentina, 5Consejo Nacional de Investigaciones Científicas y Técnicas, Unidad de Tecnología Farmacéutica,
Córdoba, Argentina
There is a need for new vaccine adjuvant strategies that offer both vigorous
antibody and T-cell mediated protection to combat difficult intracellular pathogens and
cancer. To this aim, we formulated class-B synthetic oligodeoxynucleotide containing
unmethylated cytosine-guanine motifs (CpG-ODN) with a nanostructure (Coa-ASC16
or coagel) formed by self-assembly of 6-0-ascorbyl palmitate ester. Our previous
results demonstrated that mice immunized with ovalbumin (OVA) and CpG-ODN
formulated with Coa-ASC16 (OVA/CpG-ODN/Coa-ASC16) elicited strong antibodies
(IgG1 and IgG2a) and Th1/Th17 cellular responses without toxic systemic effects.
These responses were superior to those induced by a solution of OVA with CpG-ODN
or OVA/CpG-ODN formulated with aluminum salts. In this study, we investigated
the capacity of this adjuvant strategy (CpG-ODN/Coa-ASC16) to elicit CD8+ T-cell
response and some of the underlying cellular and molecular mechanisms involved
in adaptive response. We also analyzed whether this adjuvant strategy allows a
switch from an immunization scheme of three-doses to one of single-dose. Our
results demonstrated that vaccination with OVA/CpG-ODN/Coa-ASC16 elicited an
antigen-specific long-lasting humoral response and importantly-high quality CD8+
T-cell immunity with a single-dose immunization. Moreover, Coa-ASC16 promoted
co-uptake of OVA and CpG-ODN by dendritic cells. The CD8+ T-cell response
induced by OVA/CpG-ODN/Coa-ASC16 was dependent of type I interferons and
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independent of CD4+ T-cells, and showed polyfunctionality and efficiency against an
intracellular pathogen. Furthermore, the cellular and humoral responses elicited by the
nanostructured formulation were IL-6-independent. This system provides a simple and
inexpensive adjuvant strategy with great potential for future rationally designed vaccines.
Keywords: CpG-ODN, nanostructure, vaccine, adjuvant, CD8+ T-cell response, type I interferons, ascorbyl
palmitate ester
INTRODUCTION
Most current vaccines rely on antibody production for
protection but fail to generate robust T-cell immunity crucial
for combating intracellular pathogens and cancer (1, 2). To
overcome this challenge, new adjuvant strategies are being
developed worldwide in experimental models or in human
clinical trials (3–5). Among them, there is a special interest
on synthetic oligodeoxynucleotides containing unmethylated
cytosine-guanine motifs (CpG-ODN), agonists of Toll-like
receptor 9. The key features of CpG-ODN used as a vaccine
adjuvant, in contrast to currently licensed adjuvants, include the
ability to elicit antibody, Th1-like over a Th2-like CD4+ T-cell
response and, but only under certain conditions, CD8+ T-cell
immunity. Over the last decade many human clinical trials have
been carried out with CpG-ODN, some of which are in phase
III trials in the vaccine area (6–9). Most recently, CpG-ODN has
been used as adjuvant in a vaccine (Heplisav-B) licensed by FDA,
indicated for the prevention of infection caused by Hepatitis
B Virus in adults 18 years of age and older (10). However,
the use of free CpG-ODN still presents some limitations such
as unfavorable pharmacokinetics/biodistribution patterns, high
binding to plasma proteins, lack of specificity for target cells and
poor cellular uptake that subsequently restricts its bioavailability
(9, 11–13). Hence, there is great interest in developing efficient
strategies to sort these difficulties and optimize the CpG-ODN
immunostimulatory activity. To this end, multiple strategies such
as nano/microparticles construed in a variety of ways using
different materials and self-assembled DNA nanostructures have
been explored. Although most of these formulations appeared
promising, some of them also had some problems mainly related
to manufacturing issues, such as the scaling-up of production,
and toxicity associated with cationic materials (11, 12, 14,
15).
In order to optimize the adjuvant activity of CpG-ODN,
we formulated it with a nanostructure (Coa-ASC16 or coagel)
formed by self-assembly of 6-O-ascorbyl palmitate ester (ASC16).
Our previous results demonstrated that the nanostructured
formulation of ovalbumin (OVA) and CpG-ODN with Coa-
ASC16 (OVA/CpG-ODN/Coa-ASC16) remarkably enhanced
Abbreviations: 1actA Lm-OVA, attenuated Listeria monocytogenes 10403s
strain with OVA construct; ASC16, 6-O-ascorbyl palmitate ester; CFA,
Complete Freund’s Adjuvant; CFU, Colony Forming Unit; Coa-ASC16 or
coagel, nanostructure; CpG-ODN, synthetic oligodeoxynucleotides containing
unmethylated cytosine-guanine motifs; DCs, dendritic cells; IFN-I, type I
interferons; KSCN, potassium thiocyanate; Lm-OVA, Listeria monocytogenes
10403s strain with OVA construct; LN, lymph nodes; OD, optical density; OVA,
ovalbumin; SIINFEKL, H-2Kb restricted OVA257−264; WT, wild-type.
humoral (IgG1, IgG2a) and cellular (Th1 and Th17) responses
in comparison to the soluble counterpart (OVA/CpG-ODN)
under a three-dose immunization scheme. When compared the
efficiency of CpG-ODN/Coa-ASC16 with CpG-ODN formulated
in aluminum salts, we observed that the immunization with
OVA/CpG-ODN/Coa-ASC16 was significantly more efficient
than CpG-ODN/Al(OH)3 to induce specific humoral (IgG1 and
IgG2a), Th1 and Th17 cellular immune responses. In addition,
our preclinical systemic toxicology studies performed at days 21
and 197 after first immunization showed than CpG-ODN/Coa-
ASC16 did not induce adverse biological effects (16).
ASC16 is an amphiphilic molecule composed of an ascorbic
acid polar headgroup attached to a palmitic acid nonpolar
hydrocarbon chain. When an aqueous dispersion of ASC16
is heated above the critical micelle temperature, at which the
solubility reaches the critical micelle concentration, aggregates
form a gel phase. Upon cooling below the critical micelle
temperature, Coa-ASC16 is formed. Our previous studies showed
that Coa-ASC16 is a hydrated crystalline phase and their lamellar
structure produces at least one highly ordered dimension, so they
exhibit sharp X-ray diffraction patterns and optical birefringence.
The surfactant hydrocarbon chains have limited freedom of
motion, with an interlayer distance of about 10 Å, water occupies
the space between the surfactant lamellae (17). After adding
CpG-ODN and OVA (both hydrophilic components), the study
of behavior of the H2O interlayers suggests that they are situated
in the aqueous interlamellar domain (18). A schematic picture
of this system is shown in Figures 1A,B. Coa-ASC16 has many
advantages that make it a very attractive platform for biomedical
use: (i) it is formed by two biodegradable components (ascorbic
acid and palmitic acid), (ii) ASC16 is listed as a Generally
Recognized as Safe substance, and (iii) it is easy to prepare and
inexpensive.
The purpose of the present study was to investigate the
capacity of this new adjuvant strategy (CpG-ODN/Coa-ASC16)
or free CpG-ODN to elicit CD8+ T-cell response and some
of the underlying cellular and molecular mechanisms involved
in adaptive response. We also analyzed whether this adjuvant
strategy allows a switch from an immunization scheme of three-
doses to one of single-dose. Our results demonstrated that
vaccination with OVA/CpG-ODN/Coa-ASC16 induced long-
lasting humoral response and importantly-high quality CD8+
T-cell immunity with a single-dose immunization. The CD8+
T-cell response induced by OVA/CpG-ODN/Coa-ASC16 was
dependent of type I interferons (IFN-I) and independent of
CD4+ T cells, and showed polyfunctionality and efficiency
against an intracellular pathogen. Furthermore, the cellular and
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FIGURE 1 | The formulation of OVA and CpG-ODN with the nanostructure. (A) Schematic representation of Coa-ASC16 and photographic image. (B) Schematic
representation of OVA/CpG-ODN/Coa-ASC16. (C) Native-PAGE of formulations using IRDye® 680RD OVA and 5′ IRDye® 800CW CpG-ODN comparing non-treated
and heat-treated samples (marked with asterisk).
humoral responses elicited by the nanostructured formulation
were IL-6-independent. Therefore, the present work helps to
understand the mechanism of action of this new adjuvant




Wild-type (WT) C57BL/6 mice were purchased from Fundación
Facultad de Ciencias Veterinarias (Universidad Nacional de
La Plata, La Plata, Argentina), Il6−/− and Cd8a−/− mice
from Jackson Laboratory (Bar Harbor, ME, USA). Ifnar1−/−
mice were kindly provided by Dr. M. Albert (Institut Pasteur,
Paris, France). All mice were bred in our animal facility
in accordance with the standards of the Guide to the Care
and Use of Experimental Animals, published by the Canadian
Council on Animal Care; with the assurance number A5802-01
delivered by the Office of Laboratory Animal Welfare (NIH).
The experiments were conducted on 8–12 weeks-old female
mice following protocol approved by the Institutional Animal
Experimentation Committee, Facultad de Ciencias Químicas,
Universidad Nacional de Córdoba in Argentina (# 907/2015) and
by the Institutional Animal Care and Use Committee from USA
(# AP007-SPS1-0116).
Reagents
OVA was from Worthignton Biochemical Corporation
(Lakewood, NJ, USA). A Detoxi-GelTM Endotoxin Removing
column (Thermo Fisher Scientific, Buenos Aires, Argentina)
was used to reduce the endotoxin level of the OVA stock
solution up to <1 EU/ml (Endosafe Test, Charles River,
Wilmington, MA, USA). Class-B CpG-ODN 1826 [5′-TCC
ATGACGTTCCTGACGTT-3′] with total phosphorothioate-
modified was used (Operon Technologies, Alameda, CA, USA).
The endotoxin content in CpG-ODN after reconstitution,
determined by a standard Limulus amebocyte lysate assay
(BioWhittaker Inc., Walkersville, MD, USA) was <1 EU/ml.
5′ IRDye R© 800CW CpG-ODN 1826 was synthesized by IDT
(San Diego, CA, USA) and OVA was labeled with IRDye R©
680RD using the IRDye R© 680 Protein Labeling Kit-high
MW (LI-COR Biosciences, Lincoln, NE, USA) according
to manufacturer’s instructions. Alexa Fluor 647 R© OVA
was purchased from Thermo Fisher Scientific and 5′ Alexa
Fluor 488 R© CpG-ODN 1826 from IDT. ASC16 was from
Fluka Analytical (Milan, Italy) and the H-2Kb restricted
OVA257−264 (SIINFEKL) peptide from Invivogen (San Diego,
CA, USA). Sterile apyrogenic 5% dextrose solution was
from Roux-Ocefa (Buenos Aires, Argentina) and Complete




OVA and/or CpG-ODN were added to a dispersion of 2% (w/v)
ASC16 in 5% dextrose solution, heated up to 72◦C for 15min and
then left to reach room temperature as described previously (16).
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Immunization
Mice were subcutaneously injected with OVA and CpG-
ODN in solution (OVA/CpG-ODN), OVA and CpG-ODN
formulated with the Coa-ASC16 (OVA/CpG-ODN/Coa-ASC16),
OVA formulated with Coa-ASC16 (OVA/Coa-ASC16) or CpG-
ODN formulated with Coa-ASC16 (CpG-ODN/Coa-ASC16).
Each mouse was immunized with an entire volume of 250
µl equally distributed in 5 sites: the tail base, back and neck
region and both hind limbs. CpG-ODN was administered at 75
µg/mouse/dose and OVA at 6 µg/mouse/dose in all experiments
except for the one shown in Figure 3 where the dose of OVA
was reduced to 2 µg/mouse/dose. Two different immunization
schemes were used: (1) mice were immunized on days 0, 7, and
14 and (2) mice were immunized once at day 0. At different time
post immunization, blood was collected in heparinized capillary
tubes to measure the anti-OVA antibody titers in plasma.
An additional group was immunized with OVA formulated
with CFA (OVA/CFA) on days 0, 15 and 30.
In some experiments, mice were intraperitoneally injected
with anti-CD4 (GK1.5) antibody on days −2, −1, 0, and
2 of immunization (100 µg/mouse/dose) for CD4+ T-cell
depletion or isotype control (IgG). Control of depletion (see
Supplementary Figure 1).
Native-Page
Formulations were prepared using CpG-ODN and OVA coupled
to near-infrared dye at the final concentrations used to immunize.
The CpG-ODN solution was used in a proportion of 1/180
5′ IRDye R© 800CW CpG-ODN/not labeled CpG-ODN. Before
loading, half of the samples were pre-heated at 72◦C for 15min
and then cooled down to room temperature. Samples were loaded
in 5% (v/v) glycerol and resolved in a 20% polyacrylamide gel
containing no sodium dodecyl sulfate. The gel was scanned using
an Odyssey Infrared Imaging System (LI-COR Biosciences).
In vivo Cytotoxicity Assay
Splenocytes of non-immunized syngeneic mice were prepared.
Half of the cells were incubated with 10µg/mL of SIINFEKL
peptide at 37◦C for 30min, then stained with 1.5µM CFSE
(Thermo Fisher Scientific). The remaining cells were stained with
0.15µM CFSE. Immunized and non-immunized (control) mice
were intravenously injected with a 1:1 mixture of these cells
(10 × 106 of each/mouse). Splenocytes of recipient mice were
collected 24 h after transfer, and CFSE+ cells were measured by
flow cytometry. Cytotoxicity is expressed by percentage of lysis
calculated as [1–(rcontrol-rimmune)] × 100, where r is given by the
expression of %CFSElow/%CFSEhigh cells from non-immunized
and immunized mice, respectively. This assay was performed in
WT, Il6−/−, Cd8a−/−, and Ifnar1−/− recipient mice using target
cells from each mouse strain respectively.
Splenocytes Preparation and Cytokines
Quantification
To prepare splenocytes, single cell suspensions of spleen were
treated with lysing buffer (Sigma-Aldrich).
Splenocyte cultures was performed in a 96-well U-bottom
plate (Greiner Bio One, Frickenhausen, Germany) at 37◦C
with 5% CO2 in GIBCO R©RPMI 1640 medium (Thermo Fisher
Scientific) supplemented with 10% FBS (NATOCOR, Carlos
Paz, Argentina), 1% GIBCO R© GlutaMAX, 100 U/ml penicillin,
100µg/ml streptomycin (all from Thermo Fisher Scientific) and
50µM 2-mercaptoethanol (Sigma-Aldrich).
To determine IFN-γ concentration in supernatants,
splenocytes (1 × 106 cell/well) were stimulated for 72 h at
37◦C with SIINFEKL peptide (1µg/ml) or OVA (100µg/ml) and
IFN-γ measured by ELISA (IFN-γ ELISAMAXTMkit, Biolegend,
San Diego, CA, USA). The supernatant IFN-γ concentration
was calculated after subtraction of background response (cells
incubated with media).
To determine intracellular cytokines, splenocytes (3 × 106
cells/well) were stimulated for 5 h with SIINFEKL peptide
(2µg/ml) in the presence of GolgiStop (0.7µl/ml) and GolgiPlug
(1 µl/ml) (BD Bioscience, San Diego, CA, USA). In some
experiments, anti-CD107a (ID4B) antibody was added during the
incubation with the peptide/GolgiStop/GolgiPlug mix.
Flow Cytometry
Combinations of fluorochrome-labeled antibodies from
eBiosecience, Biolegend, BD Biosciences or Tonbo Biosciences
(San Diego, CA, USA) were used. To determine intracellular
cytokines, cells were surface stained with anti-CD8α (53-6.7)
and -TCRβ (H57-597) antibodies. Then, fixed/permeabilized
with Cytofix/CytopermTM Plus kit (BD Bioscience) according
to manufacturer’s instructions and stained for cytokines
using anti-TNF-α (MP6-XT22), -IFN-γ (XMG1.2) and -IL-
2 (JE56-5H4) antibodies. The co-expression of the surface
CD107a protein and the cytokines IFN-γ, TNF-α, IL-2 were
determined after subtraction of background response (cells
incubated with media) using FlowJo Boolean gating platform.
To determine SIINFEKL-Kb tetramer+ cells, splenocytes
were incubated for 15min at 4◦C with anti-TCRβ (H57-
597), -CD4 (RM4-5) and -CD8α (53-6.7) antibodies and
SIINFEKL-Kb tetramer-PE (NIH Tetramer Core Facility
at Emory University, Atlanta, GA, USA). The cells were
collected on a FACSCanto II cytometer and the data were
processed with FlowJo software (Tree Star, Ashland, OR,
USA).
Anti-OVA Antibody Titers
Antibody titers were measured by ELISA flowing a previously
described protocol (16). HRP-conjugated anti-mouse IgG
(Sigma-Aldrich), IgG1 (X56) and IgG2a/c (R19-15) (both from
BD Bioscience) were used as detection antibodies. Titer was
considered to be the reciprocal of the last plasma dilution that
yielded a value of optical density (OD) at 490 nm greater than
that of twice the mean value of reagent blank. The plasmas from
non-immunized mice were not reactive to OVA.
Determination of Antibody Avidity
96-well half area high binding plates (Greiner Bio One) were
coated with OVA (1 µg/well) in 0.1M sodium carbonate-
bicarbonate buffer (pH 9.6) and incubated overnight at 4◦C.
Plates were washed with 0.05% Tween R©20-PBS and blocked with
0.5% gelatin-PBS. Then, washed and incubated for 1 h at 37◦C
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with plasma samples at a dilution that gave an OD value at
490 nm between 1.0 and 2.0 in the standard ELISA. Following
another washing step, 50 µl of increasing concentrations (0, 0.5,
1.0, 1.5, 2.0, and 2.5M) of potassium thiocyanate (KSCN) were
added to each row of the plate for 15min. Plates were washed
and incubated with anti-mouse HPR-conjugated IgG antibody
(Sigma-Aldrich). Plates were developed by adding substrate (o-
phenylenediamine and H2O2) and OD determined at 490 nm.
The OD values in the KSCN-treated wells were expressed
as a percentage of the untreated reference well as previously
described (19).
In vivo Uptake of OVA and CpG-ODN
Mice were subcutaneously immunized in both hind limbs with
OVA/CpG-ODN or OVA/CpG-ODN/Coa-ASC16 (1.2 µg OVA
and 15 µg CpG-ODN/50 µl/site) using Alexa Fluor 647 R© OVA
and a 50:50mix of 5′ Alexa Fluor 488 R© CpG-ODN and unlabeled
CpG-ODN. Seventy-two h later, inguinal lymph nodes (LN) were
harvested from which a single cell suspension was obtained after
collagenase D (0.5 mg/ml)/DNase I (0.2 mg/ml) (Sigma-Aldrich)
treatment. Cells were pre-incubated with anti-CD16/32 (2.4G2)
and subsequently stained at 4◦C for 15min with anti-CD11c
(N418) antibody (Biolegend) for flow cytometry analysis.
Infection
Listeria monocytogenes 10403s strain with OVA construct (Lm-
OVA) and attenuated Lm-OVA (1actA Lm-OVA) were kindly
provided by Dr. Daniel Portnoy (University of California,
Berkeley, CA, USA). Mice were intravenously infected with
5 ×103 Colony Forming Units (CFU) of 1actA Lm-OVA or
1 × 105 CFU of Lm-OVA. For bacterial load quantification,
livers were homogenized in 0.2% Nonidet P-40 (Sigma-Aldrich)-
PBS and serial 10-fold dilutions were plated on BHI agar
(BD Biosciences) containing 200µg/ml streptomycin. CFU were
counted after growth for 24 h at 37◦C.
Statistical Analysis
Data were analyzed using the GraphPad Prism5 R© (GraphPad
Software, San Diego, CA, USA). In experiments with multiple
groups of mice, statistical differences between treatment groups
were compared using ANOVA and Bonferroni post test for
multiple comparisons. For comparisons between two treatment
groups, unpaired Student’s t test was used. All data were
considered statistically significant if P values were <0.05.
RESULTS
The Formulation of OVA and CpG-ODN
With the Nanostructure
Coa-ASC16-based scaffolding containing OVA and CpG-ODN
is obtained after a heating-cooling process of a mix of
three well-defined components (OVA, CpG-ODN, and ASC16)
(Figure 1B). To test whether the manufacturing process could
promote interactions between the OVA and CpG-ODN,
solutions of OVA, CpG-ODN, or OVA/CpG-ODN were heated
or left unheated and resolved by Native-PAGE after reaching
room temperature. As shown in Figure 1C, there was no
aggregate found between the OVA and the CpG-ODN after the
heating-cooling process.
Formulation of OVA/CpG-ODN With
Coa-ASC16 Optimizes Humoral and CD8+
T-Cell Responses Independently of IL-6
We have previously shown that OVA/CpG-ODN/Coa-
ASC16 elicits Th1 cellular response (16), suggesting that it
could also induce CD8+ T-cell response. To test whether
the nanostructured formulation was able to induce OVA-
specific CD8+ T-cell responses, mice were immunized with
a three-dose schedule (days 0, 7, and 14) with OVA/Coa-
ASC16, OVA/CpG-ODN, or OVA/CpG-ODN/Coa-ASC16.
On day 21, in vivo killing assays were performed. Notably,
mice immunized with OVA/CpG-ODN/Coa-ASC16 showed
a superior cytotoxic activity than mice immunized with
OVA/Coa-ASC16 or OVA/CpG-ODN (Figure 2A). Apart
from direct cytolysis mechanisms, the CD8+ T-cells can
also orchestrate a rapid host protection by crucial cytokines
secretion for the activation of both innate and adaptive
immune system (20, 21). In this regard, splenocytes
from mice immunized with OVA/CpG-ODN/Coa-ASC16
showed higher IFN-γ secretion compared to those from
mice immunized with OVA/Coa-ASC16 or OVA/CpG-ODN
(Figure 2B).
Among other cytokines, IL-6 has been widely described
as a promoter of the development of cytotoxic CD8+ T-cell
(22) and antibody immunity in different adjuvant strategies
(23–30). Since Coa-ASC16 enhances the CpG-ODN-induced
humoral response (16) and that Coa-ASC16 alone (without
antigen or CpG-ODN) is sensed by the innate immune
system with a consequent local production of high amounts
of IL-6 (31), we inquired whether this cytokine played a
role in our model. To this end, we compared the antigen-
specific immune response elicited by immunization with
OVA/CpG-ODN/Coa-ASC16 in Il6−/− vs. WT mice. The
positive effects on CD8+ T-cell and humoral responses induced
by Coa-ASC16 were not affected by the absence of IL-6
(Figures 2C–E).
Our previous studies have shown that the magnitude
of OVA-specific humoral (IgG1, IgG2a) immune response
from mice immunized with OVA/CpG-ODN/Coa-ASC16 is
dramatically superior to that from mice immunized with
OVA/CpG-ODN in solution (16). Here, we tested whether
the formulation of the CpG-ODN with Coa-ASC16 had
any impact on the quality of the humoral response. For
that, we measured the avidity of the antibodies elicited by
immunization with OVA/CpG-ODN, OVA/CpG-ODN/Coa-
ASC16 and compared themwith those generated by OVA/CFA as
a model adjuvant system. Notably, the formulation of CpG-ODN
with Coa-ASC16 improved the antibodies avidity up to a level
comparable to those exerted by immunization with OVA/CFA
(Figure 2F).
In addition, we showed that the nanostructured formulation
allows antigen dose-sparing without significantly affecting the
antibody or Th1 cellular responses induced by vaccination
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FIGURE 2 | Formulation of OVA/CpG-ODN with Coa-ASC16 optimizes humoral and CD8+ T-cell responses independently of IL-6. WT or Il6−/− mice were
immunized with OVA/Coa-ASC16, OVA/CpG-ODN, OVA/CpG-ODN/Coa-ASC16 (on days 0, 7, and 14) or OVA/CFA (days 0, 15, and 30). (A,C) In vivo killing assay
and (B,D) ex vivo IFN-γ secretion by splenocytes after stimulation with SIINFEKL peptide determined by ELISA on day 21. (E) Titers of OVA-specific IgG1 and IgG2c
in plasma determined by ELISA on day 21. (F) WT mice. Avidity OVA-specific IgG in plasma determined by ELISA using KSCN elution seven days after the last
immunization. The data show the mean ± SEM of individual values (3-4 mice/treatment group in each experiment) and are representative of two independent
experiments performed. *p < 0.05, **p < 0.01, ***p < 0.001.
FIGURE 3 | The nanostructured formulation allows antigen dose-sparing without compromise the resulting antigen-specific immune response. C57BL/6 mice were
immunized on day 0, 7, and 14 with OVA (2 µg)/CpG-ODN/Coa-ASC16 or OVA (6 µg)/CpG-ODN/Coa-ASC16. Seven days after the last immunization, plasma and
spleen were obtained. (A) Titers of OVA-specific IgG1 and IgG2c in plasma determined by ELISA. (B) Ex vivo IFN-γ secretion by splenocytes after stimulation with
OVA determined by ELISA. The data show the mean ± SEM of individual values (4 mice/treatment group in each experiment) and are representative of two
independent experiments performed. n.s., not significant.
(Figure 3). This characteristic is particularly important in cases
were antigens are difficult to obtain or require high-cost
manufacturing processes.
Together, these data demonstrated that Coa-ASC16 improves
adjuvant effect of CpG-ODN with regard to the antibody avidity
and CD8+ T-cell response. The humoral and cellular responses
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elicited by the nanostructured formulation not require IL-6
signaling.
A Single-Dose of the Nanostructured
Formulation Is Sufficient to Induce Robust
Humoral and CD8+ T-Cell Immunity
Three-dose regimens for vaccines are expensive and difficult
to complete. Therefore, we asked whether a single-dose
immunization was sufficient to induce an antigen-specific
immune response. To this end, mice were immunized only
at day 0. A single-dose with OVA/CpG-ODN/Coa-ASC16
elicited early seroconversion while OVA/CpG-ODN failed to
generate OVA-specific IgG. In addition, we measured OVA-
specific IgG after intraperitoneal challenge with OVA at
day 147 post-immunization. This secondary contact with
the antigen showed no significant effect on the humoral
response induced by OVA/CpG-ODN/Coa-ASC16. However,
mice immunized with OVA/CpG-ODN were able to seroconvert
after secondary challenge but were never able to induce IgG2c
subtype (associated with Th1-biased response) (Figures 4A,B).
In addition, we analyzed the CD8+ T-cell response at day 7 after
immunization. Mice immunized with OVA/CpG-ODN/Coa-
ASC16 showed a cytotoxic activity and IFN-γ production
comparable with the one obtained with a three-immunization
schedule while mice immunized with OVA/CpG-ODN failed to
elicit any CD8+ T-cell response (Figures 2A,B, and 5A,B). A
supplementary in vivo killing assay was performed in Cd8a−/−
mice to demonstrate that the cellular lysis observed in our
experimental model was exclusively carried out by CD8+ T-cells
(Supplementary Figure 2). Therefore, our results demonstrate
that vaccination with nanostructured formulation is able to
induce a long-lasting antibodies and robust CD8+ T-cell
responses with a single-dose. We next focus our efforts on the
study of CD8+ T-cell response.
CD8+ T-Cell Response Is CD4+ T-Cell
Independent
CD4+ T-cell help is generally required for the generation of
CD8+ T-cell response. However, it has been reported that CpG-
ODN can bypass this need and generate a help-independent
CD8+ T-cell response (32, 33). To address the question of
whether our adjuvant strategy had the same ability, we studied
the CD8+ T-cell response in OVA/CpG-ODN/Coa-ASC16
immunized mice depleted from CD4+ T-cells. Our findings
indicate that this response is help-independent (Figures 5C,D).
IFN-I Signaling Is Essential for the
Induction of CD8+ T-Cell Response
IFN-I are positive regulators of CD8+ T-cell response through
multiple direct and indirect mechanisms (34, 35), we analyzed
the CD8+ T-cell response elicited by the immunization with
OVA/CpG-ODN/Coa-ASC16 in Ifnar−/− vs. WT mice. The lack
of IFN-I signaling resulted in complete abrogation of the CD8+
T-cell response (Figures 5E,F).
The Formulation of OVA/CpG-ODN With
Coa-ASC16 Enhances in vivo Co-uptake of
OVA and CpG-ODN by Dendritic Cells
Targeting antigen and adjuvant at the same antigen presenting
cell generally results in a potent induction of effector T-cells
and therefore is an attractive strategy for vaccine development
(36). Considering the robust CD8+ T-cell response displayed
by our adjuvant strategy we speculated that the nanostructured
formulation could promote the uptake of OVA and CpG-ODN
by dendritic cells (DCs). To this aim, draining LN were collected
72 h after immunization with the different formulations.
Mice immunized with OVA/CpG-ODN/Coa-ASC16 showed the
highest total number of CD11c+ cells (Figures 6A,B). These cells
were indeed characterized by an enhanced engulfing of both OVA
and CpG-ODN in comparison to cells from mice immunized
with OVA/CpG-ODN (Figures 6C–F). In addition, despite the
fact that our system does not chemically link OVA to CpG-ODN,
mice immunized with OVA/CpG-ODN/Coa-ASC16 were able to
simultaneously load both molecules to the same CD11c+ cells
more efficiently than mice immunized with OVA/CpG-ODN
(Figures 6G,H).
The Formulation of OVA/CpG-ODN With
Coa-ASC16 Enhances Expansion and
Polyfunctionality of Effector CD8+ T-Cells
The in vivo cytotoxicity assay revealed a robust lysis rate
against target cells loaded with SIINFEKL peptide in mice
vaccinated with nanostructured formulation. Here, we analyzed
the expansion of SIINFEKL-specific CD8+ T-cells by staining
with SIINFEKL-Kb tetramer and the number of CD8+ T-
cells producing simultaneously cytokines (polyfunctionality) in
different experimental groups. The antigen-specific CD8+ T-cell
responses induced by the non-replicative vaccines (OVA/CpG-
ODN and OVA/CpG-ODN/Coa-ASC16) was compared with
that induced by the attenuated, but replicative competent live
vaccine, 1actA Lm-OVA. Mice immunized with OVA/CpG-
ODN/Coa-ASC16 presented a higher expansion of SIINFEKL-
Kb tetramer+ CD8+ T-cells than mice immunized with the
other vaccine models (Figures 7A,B). To analyze the quality
of the CD8+ T-cell response, we performed an intracellular
staining of IFN-γ, TNF-α, and IL-2. Immunization with
OVA/CpG-ODN/Coa-ASC16 showed a higher percentage and
total number of (IFN-γ+IL-2+TNF-α+) triple, (IFN-γ+IL-2+)
double, and (IFN-γ+) single positive CD8+ T-cells than the other
immunization groups (Figures 7C–E, Supplementary Figure 3
for gating strategy used). Therefore, our results show that
vaccination with nanostructured formulation cause the highest
expansion of polyfunctional CD8+ T-cells, which would correlate
with protection against intracellular infection.
CD8+ T-Cell Response Induced by
OVA/CpG-ODN/Coa-ASC16 Protects
Against Lm-OVA Infection
To test the protective capacity of OVA-specific CD8+ T-
cell response induced by the nanostructured formulation, we
challenged immunized mice with Lm-OVA and analyzed the
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FIGURE 4 | The nanostructured formulation elicits long-lasting humoral response with a single-dose immunization. C57BL/6 mice were immunized on day 0 with
OVA/CpG-ODN or OVA/CpG-ODN/Coa-ASC16. On day 147 after immunization, mice were intraperitoneally challenged with OVA. Plasma samples were collected at
different time points for determination of OVA-specific antibodies titers by ELISA. (A) Kinetics in plasma of OVA-specific IgG. (B) OVA-specific IgG2c on days 140
(pre-challenge) and 154 (post-challenge) after immunization. The data show the mean ± SEM of individual values (4 mice/treatment group in each experiment) and are
representative of two independent experiments performed. ***p < 0.001, n.s., not significant.
FIGURE 5 | CD8+ T-cell response elicited by the nanostructured formulation is CD4+ T-cell independent and IFN-I dependent. WT (A–D) or Ifnar1−/− (E–F) mice
were immunized with a single-dose (day 0) of the indicated formulations. (A,C,E) In vivo killing assay and (B, D and F) ex vivo IFN-γ secretion by splenocytes after
stimulation with SIINFEKL peptide determined by ELISA on day 7. In C and D, mice were treated on days −2, −1, 0, and 2 with anti-CD4 or isotype control (IgG)
antibodies. The data show the mean ± SEM of individual values (3-4 mice/treatment group in each experiment) and are representative of two independent
experiments performed. n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 6 | The formulation of OVA/CpG-ODN with Coa-ASC16 enhances in vivo co-uptake of OVA and CpG-ODN by DCs. C57BL/6 mice were immunized in both
hind limbs with Alexa Fluor 647-OVA/Alexa Fluor 488-CpG-ODN or Alexa Fluor 647-OVA/Alexa Fluor 488-CpG-ODN/Coa-ASC16. Seventy-two h later, cell
suspension from inguinal LN were analyzed by flow cytometry. (A) Percentage and (B) absolute number of total CD11c+ DCs. (C) Percentage and (D) absolute
number of total OVA+ CD11c+ DCs. (E) Percentage and (F) absolute number of total CpG-ODN+ CD11c+ DCs. (G) Percentage and (H) absolute number of OVA+
or CpG-ODN+ simple positive and OVA+ CpG-ODN+ double positive within CD11c+ DCs. The data show the mean ± SEM of individual values (3-4 mice/treatment
group in each experiment) and are representative of two independent experiments performed. n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001.
CD8+ T-cell response in spleen and the remaining bacterial CFU
burden in liver. In correlation with the superior expansion of
antigen-specific CD8+ T-cells (Figures 8A,B), mice immunized
with OVA/CpG-ODN/Coa-ASC16 induced a higher amount of
IFN-γ+CD107a+TNF-α+ CD8+ T-cells than mice immunized
with OVA/CpG-ODN (Figures 8C–E, Supplementary Figure 4
show gating strategy used). In concordance with these results,
mice vaccinated with nanostructured formulation were able to
remarkably reduce the bacterial load in liver. Two days after
infection, high bacterial loads were recovered in the liver of mice
vaccinated with OVA/CpG-ODN, while OVA/CpG-ODN/Coa-
ASC16-immune mice had reduced this bacterial burden by ∼2
logs (Figure 8F).
DISCUSSION
We formulated CpG-ODN with a novel nanostructure with the
aim to optimize CpG-ODN adjuvant activity and used OVA as
soluble protein antigen model. Our previous work proved that
this system is an efficient strategy to elicit strong antibodies
(IgG1 and IgG2a) and Th1/Th17 cellular responses in mice
with a three-dose immunization regimen and without toxic
systemic effects (16). However, the mechanisms whereby Coa-
AS16 improves antigen-specific immune response are still not
fully elucidated. Based on their mechanisms of action, vaccine
adjuvants are classified as immunostimulatory agents, depot
systems or vehicles (2, 4). In this regard, we have previously
shown that Coa-ASC16 promotes antigen retention at the
injection site (depot effect) and is sensed by the innate immune
system promoting a transient local inflammatory environment
involving the release of Damage-Associated Molecular Patterns,
cytokines (IL-1β, IL-6, and IL-12) and recruitment of innate cells
(neutrophils and Ly6Chigh monocytes) (31). These facts indicate
Coa-ASC16 acts as an antigen reservoir and immunostimulatory
agent. In this study, we demonstrate the ability of this adjuvant
strategy to elicit an additional effector CD8+ T-cell response
while allowing the reduction of antigen-dose and immunization
doses without significantly compromising the antigen-specific
immune response.
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FIGURE 7 | The formulation of OVA/CpG-ODN with Coa-ASC16 enhances expansion and polyfunctionality of effector CD8+ T-cells. C57BL/6 mice were immunized
on day 0 with OVA/CpG-ODN, OVA/CpG-ODN/Coa-ASC16 or 1actA Lm-OVA and euthanized on day 7 for spleen extraction. (A) Percentage of SIINFEKL-Kb
tetramer+ CD8+ T-cells. (B) Total number of SIINFEKL-Kb tetramer+ CD8+ T-cells/spleen. (C–E) CD8+ T-cell cytokine production from splenocytes after in vitro
stimulation with SIINFEKL peptide. Multiparameter flow cytometry was used to determine (C) percentage and (D) total number of cytokine producing CD8+ T-cells
expressing each of the seven possible combinations of IFN-γ, TNF-α, and IL-2, (E) fraction of total CD8+ T-cell response comprising cells expressing each of the
seven combinations of IFN- γ, TNF-α, and IL-2. For gating strategy and representative flow cytometry data, see Supplementary Figure 3. The data show the mean
± SEM of individual values (4 mice/treatment group in each experiment) and are representative of two independent experiments performed. *p < 0.05, **p < 0.01,
***p < 0.001.
The use of Coa-ASC16 to formulate OVA/CpG-ODN allows
the induction of a long-lasting antibody response with a single-
dose avoiding the need of boosts, a goal desired in prophylactic
vaccines (Figure 4). Additionally, the nanostructure improves
the antibody avidity (Figure 2F) up to a level comparable to
the one reached by using the gold standard CFA adjuvant but
also the most reactogenic of known adjuvants and hence is
unsuitable for human use. Previous studies demonstrated that
vaccines that have the ability to improve antibody response
have superior capacity to induce germinal center formation
(37–39), unique lymphoid microenvironment in which antigen-
activated B cells undergo class switching, affinity maturation,
and differentiation into memory B cells. These studies suggest
than the nanostructured formulation could modify several
mechanisms essential for germinal center formation, a potential
linkage that will be important to investigate in subsequent
studies.
CpG-ODN is able to induce CD8+ T-cell immunity only
under certain conditions. CpG-ODN is not optimally effective
to elicit this type of response when is used in a soluble
format. However, CpG-ODN is able to induce CD8+ T-cell
immunity when it is conjugate with antigen (40) or formulated
with different strategy. Here, we report that the formulation
of antigen/CpG-ODN (both molecules without conjugation)
with Coa-ASC16 improve its ability for inducing CD8+ T-cell
immunity comparable to other strategies. However, it is difficult
to compare different formulations of CpG-ODN reported in
the literature because the amount and the type of CpG ODN
and antigen as well as mouse strain are divergent. For example,
cytotoxic activity of CD8+ T-cells induced by CpG-ODN/Coa-
ASC16 with a single-dose (Figure 5) is similar to that induced
after a single immunization with CpG-ODN formulated with
a nanoemulsion (41) or CpG-ODN nanoparticulated (42) or
after two immunizations with CpG-ODN conjugated with an
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FIGURE 8 | CD8+ T-cell response induced by the nanostructured formulation protects against Lm-OVA infection. C57BL/6 mice were immunized on day 0 with
OVA/CpG-ODN, OVA/CpG-ODN/Coa-ASC16 or CpG-ODN/Coa-ASC16. Seven days later, immunized and non-immunized mice were intravenously infected with 1 ×
105 CFU of Lm-OVA. Two days after infection, mice were euthanized for liver and spleen extraction. (A) Percentage of SIINFEKL-Kb tetramer+ CD8+ T-cells in
spleen. (B) Total number of SIINFEKL-Kb tetramer+ CD8+ T-cells/spleen. (C–E) CD8+ T-cell cytokine production from splenocytes after in vitro stimulation with
SIINFEKL peptide. Multiparameter flow cytometry was used to determine (C) percentage and (D) total number of CD8+ T-cells expressing each of the seven possible
combinations of IFN-γ, TNF-α, and CD107a, (E) the fraction of the total CD8+ T-cell response comprising cells expressing each of the seven combinations of IFN-γ,
TNF-α and CD107a. For gating strategy and representative flow cytometry data, see Supplementary Figure 4. (F) Bacterial load in liver. The data show the mean ±
SEM of individual values (3–4 mice/treatment group in each experiment) and are representative of two independent experiments performed. n.s., not significant,
*p < 0.05, **p < 0.01, ***p < 0.001.
albumin-binding lipid (43). The formulation with Coa-ASC16
has the advantage that is a simple and inexpensive platform.
Regarding the powerful CD8+ T-cell response observed
by a single immunization with OVA/CpG-ODN/Coa-ASC16
(Figure 5), we attributed this phenomenon to two main
factors. First, the nanostructured formulation clearly elicits a
higher antigen-specific CD8+ T-cell expansion than the other
formulations including the live vaccine vector, 1actA-Lm-OVA
(Figures 7A,B). Second, the characterization of this response
revealed a high degree of polyfunctionality including IFN-
γ+TNF-α+IL-2+ triple positive CD8+ T-cells (Figures 7C–E),
which often correlates with better protection against infection.
For example, this phenomenon was previously demonstrated
in mice vaccinated against T. cruzi using adenovirus vector
(44), and in mice vaccinated against malaria with adenoviral
and modified vaccinia virus Ankara vectors (45). In addition,
human polyfunctional CD8+ T-cells correlate with protection
in HIV and Mycobacterium tuberculosis infection (46–49).
Consistently with these findings, antigen-specific effector CD8+
T-cells induced by OVA/CpG-ODN/Coa-ASC16, after challenge
with Lm-OVA, showed higher efficiency to combat this
bacterial intracellular infection than the other immunization
strategies (Figure 8F). Additionally, it has been described that
polyfunctional IFN-γ+TNF-α+IL-2+ CD8+ T-cells have higher
capacity for surviving and providing greater memory protection
compared with those that produce only one cytokine (50, 51).
Therefore, the high number of polyfunctional CD8+ T-cells
observed in mice immunized with OVA/CpG-ODN/Coa-ASC16
reveals the potential of this adjuvant strategy for developing
memory CD8+ T-cell immunity, the ultimate goal for vaccines.
This issue is currently under investigation by our group.
Seeking to explore in more detail the mechanisms by which
the Coa-ASC16 improves the antigen-specific immune response,
we focused on IL-6. This cytokine has been described as a
promoter of the T-follicular helper cells differentiation and
germinal center activation (24) and hence it has been reported as
Frontiers in Immunology | www.frontiersin.org 11 October 2018 | Volume 9 | Article 2319
Chiodetti et al. CpG-ODN Induces CD8+ T-Cell Response
a key player for enhancing humoral response in many adjuvant
strategies (25–30). Despite that we have previously reported local
high levels of IL-6 released in response to Coa-ASC16 injection
(31), the lack of this cytokine had no effect in the enhancer
of magnitude or antibody isotype switching of the humoral
response elicited by the nanostructured formulation with a three-
dose schedule (Figure 2E). Yet, its possible role on inducing
an earlier seroconversion or somatic hypermutation within the
germinal center needs further elucidation. Moreover, the role of
IL-6 on the improvement of humoral response in vivo is still
controversial. It has been shown that although IL-6 may play a
significant role during early stages of the immune response, its
impact on late stages is low (52, 53). Other reports even suggest
that in certain models, the absence of IL-6 can be compensated
by other cytokines such as IL-21 and IL-27 (24). In relation to
CD8+ T-cell response, several reports showed that IL-6 plays
a role in the promotion of effector response in viral infections
(54) or in vaccination using monophosphoryl lipid A/alum as
adjuvant (22). In contrast, we found that IL-6 is not necessary
to induce CD8+ T-cell response by OVA/CpG-ODN/Coa-ASC16
(Figures 2C,D). Collectively, the considerable variation among
the molecular mechanisms found to be involved in different
adjuvant systems, highlights the importance of studying each
individual system separately.
Although the complete mechanism by which this
nanostructured formulation works is yet unknown, we speculate
that the slow antigen release (31) is the main reason why we
observed a similar long-lasting humoral and an effector CD8+ T-
cell response after reducing the number of immunizations from
three doses to one (Figures 4, 5A). A similar outcome is observed
when reducing to one third the antigen dose, demonstrating the
Coa-ASC16 ability for dose-sparing (Figure 3).
It is important that our vaccine model mimics the
composition of a subunit vaccine (based on highly purified or
recombinant antigens). In order for this kind of vaccine to elicit
a CD8+ T-cell response, the nature of antigen (particulate/non-
particulate, conjugate/unconjugated with adjuvant) and the
inflammatory environment in which the DCs encounter the
antigen are extremely important. A proper inflammatory
environment at the injection site and draining LN provide the
signals necessary for activation/maturation of DCs and the
nature of the antigen impact on the efficiency of antigen uptake
and presentation by DCs (55). Particularly, for an exogenous
antigen like OVA to be presented by DCs to naïve CD8+
T-cells, it must undergo a process called cross-presentation
(56). This process, in addition to antigen cytosolic delivery
into DCs, require co-association of signal of an appropriate
adjuvant to the same DCs (36). In mice, resident CD8+ DCs
and migratory CD103+ DCs have been described as the most
efficient cross-presenting DCs. Moreover, pDCs has been shown
to efficiently cross-present when stimulated by TLR ligands
(57). Cross-presentation can be facilitated by signals deployed
by intracellular Toll-like receptors agonists like CpG-ODN
and/or cytokines like IFN-I, among others (34, 35, 58, 59).
To secure the co-localization of both molecules within the
same DCs, several adjuvants strategies involving CpG-ODN
used chemical or physical conjugations between the antigen
and the CpG-ODN (40, 60). In this work, we found that the
nanostructured formulation is able to induce a strong CD8+
T-cell response and that requires both, CpG-ODN and IFN-I
signaling. This is proved by our findings where immunization
with OVA/Coa-ASC16 or the abrogation of IFN-I pathway
completely impairs CD8+ T-cell response (Figures 2A,B, 5E,F).
The CpG-ODN-dependency for exerting a CD8+ T-cell response
suggests that the co-localization of OVA and CpG-ODN by the
same DCs is important for its licensing and posterior priming
of naïve CD8+ T-cells. In this regard, we have shown that
our adjuvant strategy promotes the co-uptake of OVA and
CpG-ODN by DCs in draining LN (Figure 6G,H) despite being
offered in an unconjugated manner (Figure 1C). These results,
combined with the efficacy of CD8+ T-cell response, invite us to
elucidate which subset of DCs could be involved in this process
and to understand how this nanostructure promotes co-uptake
of both molecules. The characterization of this phenomenon will
allow us to confirm if there is a strict link between uptake, cross-
presentation and the optimizing of activation of CD8+ T-cell
(cross-priming). Although these inquiries remain unknown, we
hope to address them on the near future.
Focusing on IFN-I, it is still unclear whether its production
is being elicited by the CpG-ODN or/and the Coa-ASC16.
Nevertheless, this fact is specially intriguing since we used a type
of CpG-ODN that belongs to class-B family. As a consequence
of its structure, class-B CpG-ODN are not characterized for
inducing IFN-I as other CpG-ODN families such as class-A CpG-
ODN (13). A possible mechanism involved in the induction
of these cytokines might be related to the Coa-ASC16 itself. It
has been reported that self or pathogen dsDNA can activate
cytosolic DNA sensor proteins inducing the production of IFN-I
(61). Considering Coa-ASC16 ability for inducing in vivo death
of resident cells at the injection site with the transient release
of Damage-Associated Molecular Patterns as dsDNA previously
shown (31), this nanostructure might be triggering the secretion
of IFN-I by the activation of cytosolic DNA sensor proteins.
Yet, the fact that self dsDNA could additionally activate Toll-like
receptor 9 pathway should not be dismissed. Here, we present an
adjuvant strategy that efficiently induced IFN-I dependent CD8+
T-cell response using class-B CpG-ODN not conjugated with
the antigen. This is a desired effect for two main reasons. First,
free class-ACpG-ODN aggregates into uncontrolled higher order
structures of different sizes that are unpredictable and hence not
suitable for clinical applications (13). Second, the conjugation of
a protein with CpG-ODN can disrupt the structure of the antigen
affecting its properties (62).
In summary, these data indicate that the formulation
system presented herein strongly optimizes CpG-ODN adjuvant
activity thus enhancing quantitatively and qualitatively both
humoral and CD8+ T-cell responses with a single-dose, thus
providing a substantive vaccine platform for use with subunit
antigens. In addition, this system offers most of the desired
effects in a vaccine adjuvant such as allowing the reduction
of the number of immunizations and dose-sparing without
compromising the resulting immune response while offering a
simple, biocompatible, and inexpensive system that could easily
scale up to massive production.
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